<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article307</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/MPACT" style="display:block; margin-bottom:10px;">MPACT Original</a></li>
<h2><strong>MPACT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer". The New England Journal of Medicine. 2013.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with metastatic pancreatic cancer, does the addition of nab-paclitaxel to gemcitabine improve survival compared with gemcitabine monotherapy?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with metastatic pancreatic adenocarcinoma, the addition of nab-paclitaxel to gemcitabine resulted in significantly enhanced overall survival, progression-free survival, and response rate, albeit with elevated rates of peripheral neuropathy and myelosuppression.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
A phase 3 study showed that the combination of nab-paclitaxel and gemcitabine led to a notable survival advantage for patients with metastatic pancreatic cancer over treatment with gemcitabine alone. Key findings included improved median overall survival by 1.8 months and a doubling in the 2-year survival rate with the combination therapy.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of 2013, there are no specific guidelines that reference the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, open-label, randomized, phase 3 trial.<br/>
- N=861 patients with metastatic pancreatic cancer.<br/>
- Nab-paclitaxel plus gemcitabine (n=431) versus gemcitabine (n=430).<br/>
- Setting: 151 community and academic centers in 11 countries.<br/>
- Enrollment: May 2009 to April 2012.<br/>
- Analysis: Intention-to-treat.<br/>
- Primary outcome: Overall survival.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Adults (≥18 years) with metastatic adenocarcinoma of the pancreas.<br/>
- Karnofsky performance-status score of 70 or more required.<br/>
- Patients had not previously received chemotherapy for metastatic disease.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Nab-paclitaxel (125 mg per square meter) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.<br/>
- Gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles).<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Median overall survival: Nab-paclitaxel–gemcitabine group 8.5 months, gemcitabine group 6.7 months (HR 0.72, 95% CI, 0.62 to 0.83; P&lt;0.001).<br/>
- Median progression-free survival: 5.5 months in the nab-paclitaxel–gemcitabine group versus 3.7 months in the gemcitabine group (HR 0.69, 95% CI, 0.58 to 0.82; P&lt;0.001).<br/>
- Overall response rate (independent review): 23% in the nab-paclitaxel–gemcitabine group versus 7% in the gemcitabine group (P&lt;0.001).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Quality of life was not measured.<br/>
- The study's open-label design might have influenced assessments.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Celgene.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The New England Journal of Medicine, published on October 16, 2013, at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
